October 22, 2018 / 2:49 PM / 24 days ago

BRIEF-Roche Says Phase III Study On Alecensa Meets Primary Endpoint

Oct 22 (Reuters) - Roche Holding AG:

* SAYS WILL TO ANNOUNCE RESULTS FROM THE PHASE III ALESIA STUDY, SHOWING THAT ALECENSA® (ALECTINIB) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED (INV) PROGRESSION-FREE SURVIVAL (PFS)

* ALECENSA (ALECTINIB) SIGNIFICANTLY REDUCED RISK OF DISEASE WORSENING OR DEATH AS FIRST-LINE TREATMENT IN ASIAN PATIENTS WITH ALK-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below